Fibronostics, a global leader in non-invasive diagnostics for metabolic and liver diseases, announces the completion of its acquisition of Stone Clinical Laboratories, LLC, a leading provider of advanced laboratory services in the United States. This strategic acquisition strengthens Fibronostics’ research and development position and reinforces its commitment to innovation in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD). The transaction comes at a pivotal time for the industry, following major milestones such as the FDA approvals of Madrigal Pharmaceuticals’ Rezdiffra™ and Novo Nordisk’s Wegovy®, as well as Roche’s acquisition of 89Bio.
Read the full article: Fibronostics Acquires Stone Clinical Laboratories to Advance MASH/MASLD Diagnostics //
Source: https://www.prnewswire.com/news-releases/fibronostics-acquires-stone-clinical-laboratories-to-advance-mashmasld-diagnostics-302595432.html